What is the price of Noxopharm Limited (NOX)

The price of Noxopharm Limited (NOX) is $0.0416118

What is the market cap of Noxopharm Limited (NOX)

The market cap of Noxopharm Limited (NOX) is $12.78M

Noxopharm Limited (NOX) P/B Ratio

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Year	P/B Ratio	Change
2026 (TTM)	-15.81	-169.07%
2025	22.89	552.09%
2024	3.51	153.44%
2023	1.39	-41.18%
2022	2.35	-43.58%
2021	4.17	135.34%
2020	1.77	-100.32%
2019	-557.47	-8,922.40%
2018	6.32	-44.76%
2017	11.44	1,140.62%
2016	0.92	0.00%

Year

P/B Ratio

Change

2026 (TTM)

-15.81

-169.07%

2025

22.89

552.09%

2024

3.51

153.44%

2023

1.39

-41.18%

2022

2.35

-43.58%

2021

4.17

135.34%

2020

1.77

-100.32%

2019

-557.47

-8,922.40%

2018

6.32

-44.76%

2017

11.44

1,140.62%

2016

0.92

0.00%

Company	P/B Ratio	P/B Ratio Difference	Country
Novo Nordisk A/S NVO.US	5.6573	-135.78%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	6.3842	-140.38%	US
Regeneron Pharmaceuticals, Inc. REGN.US	2.4551	-115.53%	US
UCB SA UCB.BR	4.364	-127.60%	BE
CSL Limited CSL.AX	2.5504	-116.13%	AU

Company

P/B Ratio

P/B Ratio Difference

Country